TRAIL

Y V Lomovskaya1, K S Krasnov1, M I Kobyakova1,2

  • 1Institute of Theoretical and Experimental Biophysics of the Russian Academy of Sciences, Pushchino, Moscow region, 142290 Russian Federation.

Acta naturae
|May 3, 2024
PubMed
概括

这项研究确定了Interleukin-1 Beta (IL1B) 作为急性骨髓性白血病 (AML) 细胞对瘤亡因子相关的亡诱导合体 (TRAIL) 耐药性的关键调节剂. 这一发现为AML治疗耐药性提供了新的见解.